Avidity Biosciences Inc’s filing revealed that its Officer KATHLEEN GALLAGHER acquired Company’s shares for reported $0.58 million on Feb 03 ’25. In the deal valued at $32.93 per share,17,625 shares were bought.
Then, LEVIN ARTHUR A sold 1,872 shares, generating $53,537 in total proceeds. Upon selling the shares at $28.60, the Director now owns 12,958 shares.
Before that, MacLean Michael F sold 3,287 shares. Avidity Biosciences Inc shares valued at $93,985 were divested by the Chief Financial Officer at a price of $28.59 per share. As a result of the transaction, MacLean Michael F now holds 104,655 shares, worth roughly $3.34 million.
H.C. Wainwright initiated its Avidity Biosciences Inc [RNA] rating to a Buy in a research note published on December 20, 2024; the price target was $72. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in late November with a ‘”an Outperform”‘ rating. Goldman began covering RNA with “Buy” recommendation on September 24, 2024. Barclays started covering the stock on August 28, 2024. It rated RNA as “an Overweight”.
Price Performance Review of RNA
On Monday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock fall -2.95% to $31.96. Over the last five days, the stock has gained 4.99%. Avidity Biosciences Inc shares have risen nearly 9.90% since the year began. Nevertheless, the stocks have risen 161.32% over the past one year. While a 52-week high of $56.00 was reached on 01/31/25, a 52-week low of $11.23 was recorded on 01/14/25. SMA at 50 days reached $33.89, while 200 days put it at $37.97.
Levels Of Support And Resistance For RNA Stock
The 24-hour chart illustrates a support level at 31.36, which if violated will result in even more drops to 30.75. On the upside, there is a resistance level at 32.68. A further resistance level may holdings at 33.39. The Relative Strength Index (RSI) on the 14-day chart is 51.64, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.16, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 26.94%. Stochastics %K at 84.25% indicates the stock is a selling.
How much short interest is there in Avidity Biosciences Inc?
A steep rise in short interest was recorded in Avidity Biosciences Inc stocks on 2025-01-15, dropping by 87013.0 shares to a total of 15.39 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 15.48 million shares. There was a decline of -0.57%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 03, 2024 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $40 price target.
